Processing

Please wait...

Settings

Settings

Goto Application

1. WO2006086561 - NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS

Publication Number WO/2006/086561
Publication Date 17.08.2006
International Application No. PCT/US2006/004599
International Filing Date 08.02.2006
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 39/42 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
A61K 39/215 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
CPC
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • NEW YORK BLOOD CENTER [US]/[US] (AllExceptUS)
  • JIANG, Shibo [US]/[US] (UsOnly)
  • HE, Yuxian [CN]/[US] (UsOnly)
Inventors
  • JIANG, Shibo
  • HE, Yuxian
Agents
  • CHAN, Albert, Wai-Kit
Priority Data
11/141,92531.05.2005US
60/651,04608.02.2005US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS
(FR) NEUTRALISATION D'ANTICORPS MONOCLONAUX CONTRE LE CORONAVIRUS ASSOCIE AU SYNDROME RESPIRATOIRE AIGU SEVERE
Abstract
(EN)
The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
(FR)
L'invention concerne un anticorps isolé capable de se lier au domaine de liaison au récepteur de la protéine spicule du coronavirus associé au syndrome respiratoire aigu sévère (SARS-CoV) afin d'inhiber, de manière compétitive, la liaison du SARS-CoV avec des cellules hôtes. On peut utiliser ces mAbs ou substances: 1) comme agents d'immunisation passive pour prévenir une infection par le SARS-CoV; 2) comme réactifs biologiques pour diagnostiquer une infection par le SARS-CoV; 3) comme thérapies immunitaires pour traiter précocement une infection par le SARS-CoV; et 4) comme sondes pour étudier l'immunogénicité, l'antigénicité, la structure et la fonction de la protéine SARS- CoV S.
Latest bibliographic data on file with the International Bureau